18910-68-4

Usage

Uses

Used in Pharmaceutical Quality Control:
Levalbuterol Related Compound B (20 mg) (alpha-[(1,1-Dimethylethyl)aminomethyl]-4-hydroxy-3-methyl-benzenemethanol) is used as an impurity reference standard for the quality control of pharmaceutical products, specifically for Levalbuterol, which is a medication used in the treatment of asthma and other respiratory conditions. Its application ensures the safety, efficacy, and purity of the final drug product.
Used in Research and Development:
In the field of pharmaceutical research and development, Levalbuterol Related Compound B (20 mg) (alpha-[(1,1-Dimethylethyl)aminomethyl]-4-hydroxy-3-methyl-benzenemethanol) serves as a valuable reference compound for the synthesis, characterization, and optimization of new drugs targeting β-adrenergic receptors. Its use in research helps in understanding the structure-activity relationship of these receptors and contributes to the development of more effective and safer medications for respiratory diseases.
Used in Regulatory Compliance:
Levalbuterol Related Compound B (20 mg) (alpha-[(1,1-Dimethylethyl)aminomethyl]-4-hydroxy-3-methyl-benzenemethanol) is also utilized in the regulatory compliance process for pharmaceutical manufacturers. It helps in meeting the regulatory requirements for drug quality, safety, and efficacy, ensuring that the final drug product meets the necessary standards before being released to the market.

Upstream product

• 24085-07-2 3'-acetoxymethyl-4'-acetoxy-2-bromoacetophenone 
• 60853-66-9 2-tert-Butylamino-1-(4-hydroxy-3-methyl-phenyl)-ethanone 
• 41877-17-2 2-bromo-1-(4-hydroxy-3-methylphenyl)ethan-1-one 
• 876-02-8 4-hydroxy-3-methylphenyl methyl ketone 
• 24085-03-8 α-[(benzyl-tert-butylamino)methyl]-m-xylene-4,α,α'-triol 

Relevant academic research and scientific papers

Preparation method and application of salbutamol impurity

The invention discloses a preparation method and application of a salbutamol impurity. The preparation method adopts the following process route of taking 2-acetoxy-5-(2-bromoacetyl) benzyl acetate (ABBA) as an initial raw material, and firstly reacting w

A Combined High-Throughput Screening and Reaction Profiling Approach toward Development of a Tandem Catalytic Hydrogenation for the Synthesis of Salbutamol

A combined high-throughput screening and reaction profiling approach to the telescoping of two reductions in the synthesis of Salbutamol is described. Optimization studies revealed the beneficial effect of mildly acidic conditions, and the use of water as a cosolvent. Persistent formation of deoxygenated impurities using a Pd/C catalyst led to the initiation of reaction profiling studies, which revealed that the ketone intermediate formed after rapid debenzylation is the sole source of deoxygenated impurities, indicating that more rapid ketone hydrogenation should minimize this deoxygenation. A dual catalyst approach based on these insights has been developed, with both Pd/Pt and Ru/Pt catalyst systems as more selective than Pd-only systems. Based on reaction profiles that indicate the deoxygenation side reaction is first-order in the concentration of debenzylated ketone intermediate, Pt catalysts for rapid and selective ketone hydrogenation were paired with Pd and Ru catalysts known to perform selective debenzylation. Optimization of these dual catalyst processes led to conditions that were demonstrated on 20 g scale to prepare Salbutamol in 49% isolated yield after recrystallization.